Clinical trial
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and…
NCT00331344 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00331344 |
|---|---|
| Title | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy |
| Official title | Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug |
| Interventions | mitoxantrone hydrochloride, ixabepilone, prednisone |
| Enrollment | 100 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | May 31, 2006 |
| Last update posted | Oct 31, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: